

Antimicrobial Stewardship

Syndromic and System-Level Interventions

Collaborators





More resources available at:
<https://dchealth.dc.gov/dcrx>

Course Overview

- Antibiotic Overuse
 - Defining antimicrobial stewardship
 - Misuse of antibiotics
- Syndromic Stewardship
 - Defining syndromic stewardship
 - Syndromic examples
- System-level Interventions
 - Challenges
 - Strategies
- Implementation Practices

Presenters

- Kerry L. LaPlante, Pharm.D., FCCP, FIDSA
 - Chairperson, Antimicrobial Stewardship and Environmental Cleaning Task Force, Rhode Island Department of Health
 - Chairperson and Professor of Pharmacy, University of Rhode Island, College of Pharmacy
 - Adjunct Professor of Medicine, The Warren Alpert Medical School of Brown University
 - Senior Director of the Rhode Island Infectious Diseases
 - Research (RIID) Program Co-Director of Antimicrobial Stewardship Program, and Infectious Diseases Pharmacotherapy Specialist, Providence Veterans Medical Center

Presenters

- Clara Ni, PharmD, BCIDP
 - Clinical Pharmacist – Antimicrobial Stewardship, MedStar Georgetown University Hospital


Advisors

- **Barbara Bolstorff**, MPH, CIC, *Epidemiologist*, MA Dept. of Health
- **Melissa Cumming**, MS, *Epidemiologist and Statewide Antibiotic Resistance Coordinator*, MA Dept. of Health
- **Glenn Wortmann**, MD, FIDSA, FACP, *Section Director of Infectious Disease, MedStar and Professor of Clinical Medicine, Georgetown University*
- **Kimberly Sommers**, MD, *Team Lead for the Guidance and Policy Team*, DC Health

Conflicts of Interest

- None of the speakers or advisors have a conflict of interests to declare.

Important Information



The video will progress at its own pace.



Do not attempt to speed up the video.



The video can be paused and resumed later.

DC | HEALTH

GOVERNMENT OF THE DISTRICT OF COLUMBIA

899 North Capitol Street NE, 5th Fl, Washington, DC 20002



dchealth.dc.gov



[@_DCHealth](https://twitter.com/_DCHealth)



[dchealth](https://www.instagram.com/dchealth)



[DC Health](https://www.facebook.com/DCHealth)

Antibiotic Overuse in Our Community;

A call to action

Kerry L. LaPlante, Pharm.D., FCCP, FIDSA, FIDP

Chairperson, Antimicrobial Stewardship and Environmental Cleaning Task Force, Rhode Island Department of Health
Department Chairperson and Professor of Pharmacy, University of Rhode Island, College of Pharmacy
Adjunct Professor of Medicine, The Warren Alpert Medical School of Brown University
Senior Director of the Rhode Island Infectious Diseases Research (RIID) Program
Co-Director of Antimicrobial Stewardship Program, and Infectious Diseases Pharmacotherapy Specialist, Providence Veterans Medical Center

Disclosures

Speaker Bureaus: None

Grant Investigator: Merck, Pfizer,

Advisory Committee/Boards: Merck, Entasis, Paratek, Ferring, Spero

- The information disseminated in this lecture is given in my personal capacity and not in my capacity as a VA employee nor does it necessarily reflect the views of the United States Department of Veterans Affairs or the Rhode Island Department of Health
- **This presentation will not include discussion of unapproved or investigational uses of products or devices.**

LEARNING OBJECTIVES

At the end of this presentation, the learner will be able to:

1. Discuss how **antibiotic overuse**, and a dwindling antimicrobial pipeline has led to antimicrobial resistance and subsequent public health emergency
2. Describe how a **syndromic stewardship** approach focuses efforts in an already overwhelmed and under resourced community setting
3. Describe effective **implementation** practices for antimicrobial stewardship in community settings

ANTIBIOTIC OVERUSE

Preserving a shared resource



Framework (Start with “Why”....)

- Antibiotics are a shared resource...and now a scarce resource
- Antibiotics are essential to patient safety
- Antibiotics are essential to national security
- Geriatric patients use the highest rates of antibiotics
- United States population is aging
- Antibiotics do not treat viral illness like COVID, Influenza, Common Cold




GOAL: Increase the number of antibiotic stewardship champions in DC

Bacteria evolved 3.5 BILLION years ago...



The human lineage



© Encyclopædia Britannica, Inc.

Homo sapiens, a culture-bearing upright-walking species that lives on the ground and very likely first evolved in Africa about 315,000 years ago

150 YEARS | AMERICAN MUSEUM OF NATURAL HISTORY

“Mold Juice” –The Discovery of Penicillin



St. Mary's Hospital in London in 1928. A 47 year old Alexander Fleming observed that a plate culture of *Staphylococcus* had been contaminated by a blue-green mold (*Penicillium notatum*) and that colonies of bacteria adjacent to the mold were being dissolved.



*Bacterial inhibition originally noticed by a French medical student, Ernest Duchesne, in 1896

~ Nobel Prize in Physiology or Medicine in 1945 ~

One of the most important medical events of medical history discovery and use of antibiotics...



Thanks to **PENICILLIN**
...He Will Come Home!



FROM ORDINARY MOLD—
the Greatest Healing Agent of this War!

On the sandy, green-and-yellow mold above, called *Penicillium notatum* in the laboratory, grows the miraculous substance first discovered by Professor Alexander Fleming in 1928. Named penicillin by its discoverer, it is the most potent weapon ever developed against many of the deadliest infectious known to man. Because research on molds was already a part of Schenley's extensive, Schenley Laboratories were well able to meet the problem of large scale production of penicillin, when the great need for it arose.

When the stuporous battles of this war have subsided no pages of silent print in a history book, the greatest news event of World War II may well be the discovery and development—out of some vicious secret weapon that *destroys*—but of a weapon that *saves* lives. This weapon, of course, is penicillin.

Every day, penicillin is performing some unbelievable act of healing on some far battlefield. Thousands of men will return home who otherwise would not have had a chance. Better still, more and more of this precious drug is now available for civilian use... to save the lives of patients of every age.

A year ago, production of penicillin was difficult, costly. Today, due to specially devised methods of mass-production, in use by Schenley Laboratories, Inc. and the 20 other firms designated by the government to make penicillin, it is available in ever-increasing quantities, at progressively lower cost.

Listed in "THE DOCTOR FIGHTER" magazine RAYMOND HANNEY, Tuesday edition, C. & G. Two year journal for time and money.


SCHENLEY LABORATORIES, INC.
Producers of **PENICILLIN-Schenley**



Antibiotics' Effectiveness

Antibiotics caused US deaths to decline by ~220 per 100,000 in 15 years

US Infection Death Rate per 100,000 population



Armstrong, G. L. et al. JAMA 1999;281:61-66.

Slide credit: IDSA, Public Policy & Government Relations


The Power of Antibiotics

Disease	Death Pre-Antibiotics	Death With Antibiotics	Change in Death
Community Pneumonia ¹	~35%	~10%	-25%
Hospital Pneumonia ²	~60%	~30%	-30%
Heart Valve Infection ³	~100%	~25%	-75%
Brain Infection ⁴	>80%	<20%	-60%
Skin Infection ⁵	11%	<0.5%	-10%
<i>By comparison...treatment of myocardial infarction with aspirin or streptokinase⁶</i>			-3%

¹IDSA Position Paper '08 Clin Infect Dis 47(S3):S249-65; ²IDSA/ACCP/ATS/SCCM Position Paper '10 Clin Infect Dis In Press; ³Kerr AJ. Subacute Bacterial Endocarditis. Springfield IL: Charles C. Thomas, 1955 & Lancet 1935 226:383-4; ⁴Lancet '38 231:733-4 & Waring et al. '48 Am J Med 5:402-18; ⁵Spellberg et al. '09 Clin Infect Dis 49:383-91 & Madsen '73 Infection 1:76081
⁶Lancet 2:349-60

Slide credit: IDSA, Public Policy & Government Relations

Sir Alexander Fleming on June 26, 1945:




“The microbes are **educated to resist penicillin** and a host of penicillin-fast organisms is bred out....In such cases the **thoughtless person** playing with penicillin is **morally responsible for the death of the man** who finally succumbs to infection with the penicillin-resistant organism. I hope this evil can be averted.”

Penicillin finder assays its future. New York Times 26 June 1945: 21..

Antibiotic Pipeline

A steady decline in new antibiotics






Antimicrobial Stewardship

Defined and formalized in 2007

“Coordinated interventions designed to improve and measure the appropriate use of antimicrobials by promoting the selection of the optimal antimicrobial drug regimen, dose, duration of therapy, and route of administration.”

Antibiotic “Misuse” Across Settings



Fridkin S, et al. Morbidity and Mortality Weekly Report. United States Center for Disease Control and Prevention. 2014; 63(09):194-200. and <http://www.cdc.gov> Data accessed: May 2017

NEW CDC DATA

MORE THAN HALF OF ANTIBIOTIC PRESCRIBING FOR SELECTED EVENTS IN HOSPITALS WAS NOT CONSISTENT WITH RECOMMENDED PRESCRIBING PRACTICES



ANTIBIOTIC PRESCRIBING WAS NOT SUPPORTED IN:



with community-acquired pneumonia



with urinary tract infections



prescribed fluoroquinolone treatment



prescribed intravenous vancomycin antibiotic

HOSPITAL PRESCRIBERS & PHARMACISTS CAN IMPROVE PRESCRIBING:



Optimize antibiotic selection



Re-assess antibiotic treatment when the results of diagnostic testing are available



Use the shortest effective duration of therapy

FIND RESOURCES ON HOW TO IMPROVE HOSPITAL ANTIBIOTIC USE AND HELP FIGHT ANTIBIOTIC RESISTANCE:
<http://bit.ly/HospAbx>




**BE
ANTIBIOTICS
AWARE**

SMART USE, BEST CARE


Antibiotic Misuse

- Given when they are not needed
- Continued when they are **no longer necessary**
- Given at the **wrong dose** (under-dosed)
- **Broad-spectrum** agents are used to treat susceptible bacteria
- The **wrong antibiotic** is given to treat an infection



ANTIBIOTIC RESISTANCE THREATS
IN THE UNITED STATES

2019



2020 ANTIBIOTIC USE
UPDATE IN THE UNITED STATES
PROGRESS AND OPPORTUNITIES

SYNDROMIC STEWARDSHIP

Discuss how to customize specific interventions based on local needs

What is syndromic stewardship?

Syndrome: a disease or disorder that involves a particular group of signs and symptoms



Stewardship: the careful and responsible management of something entrusted to one's care



Careful management of a particular infection

So many “Stewardship’s”

Antimicrobial Stewardship

- Right interpretation
- Right antimicrobial
- Right time

Diagnostic Stewardship

- Right test
- Right patient
- Right time

Syndromic Stewardship

- Right disease
- Right diagnosis
- Right disciplines

Syndromic Stewardship



Respiratory



Blood Culture Identification



Gastrointestinal



Meningitis/
Encephalitis



Pneumonia

Disease-based antimicrobial stewardship emphasizes improving patient outcomes by optimizing antimicrobial use and increasing compliance with performance measures


Advantages of Syndromic Stewardship

FOCUS

Define an area of need...

Multi-disciplinary

- Physicians (diagnosis)
- Laboratory (diagnostics)
- Pharmacy (antibiotics & order sets)
- Nursing (administration and assessment)




Disease Specific Stewardship



IMPROVED CLINICAL OUTCOMES

- Bloodstream infection
 - Mortality
 - Length of stay
 - Clinical success



WHY?


Mortality is already extremely high

EXAMPLE

shutterstock.com · 647778254

LIMITED IMPACT ON CLINICAL OUTCOMES

- Upper respiratory tract infections
- *Clostridioides difficile* infection
- Asymptomatic bacteriuria



WHY?

Mortality is lower

BUT...

Associated with increased antibiotic use

~ *Clostridioides difficile* ~



Designated an **URGENT** Global Threat by the CDC

“THREAT LEVEL URGENT: immediate public health threat that requires urgent and aggressive action”

- Spans all Health Care (ACF, LTCF, AmCF, Urgent Care)
- HAC (Costs 1% of CMS)
- Preventable (Patient Focused)

EXAMPLE

shutterstock.com - 642778754



CDC=Centers for Disease Control and Prevention.
CDC. Antibiotic resistance threats in the United States, 2019..
<https://www.cdc.gov/drugresistance/biggest-threats.html>




Pharmacy

Restrict FQ use
Decrease P/T use
Transition to
Tetracycline's
Implement PPI
Stewardship



Laboratory (Diagnostic)

Evaluate
PCR/Toxin Testing



Infection Prevention and Control

Environmental
Cleaning
Hand Hygiene

Antimicrobials Predisposing Patients to CDI

Most Commonly Associated with CDI

Clindamycin

Fluoroquinolones

Piperacillin/Tazobactam


Cephalosporins

Among symptomatic patients with CDI:

- 96% of patients received antimicrobials within the 14 days before onset
- 100% received an antimicrobial within the previous 3 months

Antibiotic pose increased risk to *C. difficile* infection

Linear association between a 4-point antibiotic risk index and community-associated CDI risks.



Journals.ASM.org

This content may be subject to copyright and license restrictions.
Learn more at journals.asm.org/content/permissions



Antimicrobial Agents
and Chemotherapy

Predictors of Mortality Among a National Cohort of Veterans With Recurrent *Clostridium difficile* Infection

Haley J. Appaneal,^{1,2,3} Aisling R. Caffrey,^{1,2,3,4} Maya Beganovic,^{1,2} Sanja Avramovic,⁵ and Kerry L. LaPlante^{1,2,3,6}

¹Infectious Diseases Research Program, Providence Veterans Affairs Medical Center, Providence, Rhode Island; ²College of Pharmacy, University of Rhode Island, Kingston, Rhode Island; ³Center of Innovation in Long-Term Support Services, Providence Veterans Affairs Medical Center, Providence, Rhode Island; ⁴Brown University School of Public Health, Providence, Rhode Island; ⁵Health Administration and Policy, George Mason University, Fairfax, Virginia; ⁶Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence, Rhode Island

Background. Though recurrent *Clostridium difficile* infection (CDI) is common and poses a major clinical concern, data are lacking regarding mortality among patients who survive their initial CDI and have subsequent recurrences. Risk factors for mortality in patients with recurrent CDI are largely unknown.

Independent Predictors of Mortality	Odds Ratio (95% CI)
Proton pump inhibitor (within 7 d before)	3.86 CI (2.14 – 6.96) 
Antibiotics (non CDI Tx antibiotic)	3.33 (CI 1.79 – 6.17) 
Respiratory failure	8.62 (CI 1.71 – 39.92)
Nutritional deficiency	2.91 (CI 1.37 – 6.21)
Cognitive dysfunction	2.41 (CI 1.02 – 5.72)
Age	1.04 (CI 1.01 – 1.06)

Proton Pump Inhibitors....

FDA Drug Safety Communication: Clostridium difficile associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs)

Proton-Pump Inhibitor (PPI) Use



The FDA has issued multiple warnings on the long-term use of PPIs. These include: increased risk of *C. difficile* infection³, hypomagnesemia², and fractures of the hip, wrist, and spine¹. Therefore, prudent prescribing of PPIs is warranted. The FDA recommends use of the lowest dose and shortest duration of PPI therapy appropriate for the condition being treated. ¹⁻³ Patient compliance, time of administration (prior to meals), and dietary indiscretions (i.e. alcohol or irritating foods) should be assessed prior to titration of PPI doses.

Indication	Omeprazole (Prilosec [®])	Pantoprazole (Protonix [®])
Duodenal Ulcers		
Active treatment	20 mg PO daily x 4 weeks, additional 4 weeks may be required	40 mg PO daily x 2-4 weeks
Maintenance treatment	10-20 mg PO daily; long-term use	--
<i>H. pylori</i> infection	40 mg PO daily x 14 days (dual therapy) 20 mg PO BID x 10 days (triple therapy)	--
Gastric Ulcers		
Short-term active treatment (non-NSAID)	40 mg PO daily x 4-8 weeks	40 mg PO daily x 4-8 weeks



IMPLEMENTATION

Describe effective implementation practices



Antibiotic Prescribing and Use

CDC > Antibiotic Use



Antibiotic Use

About Antibiotic Use +

Treatment for Common Illnesses +

Patient Education and Promotional Resources +

Training & Resources for Healthcare Professionals +

Antibiotic Use Data and Research +

Core Elements of Antibiotic Stewardship -

Hospital +

Outpatient +

Nursing Home +

Small and Critical Access Hospitals

Resource-Limited Settings

U.S. Antibiotic Awareness Week +

Core Elements of Antibiotic Stewardship

Antibiotic stewardship is the effort to measure and improve how antibiotics are prescribed by clinicians and used by patients. Improving antibiotic prescribing and use is critical to effectively treat infections, protect patients from harms caused by unnecessary antibiotic use, and combat antibiotic resistance.

CDC's Core Elements of Antibiotic Stewardship offer providers and facilities a set of key principles to guide efforts to improve antibiotic use and, therefore, advance patient safety and improve outcomes. These frameworks complement existing guidelines and standards from key healthcare partner organizations, including the Infectious Diseases Society of America, Society for Healthcare Epidemiology of America, American Society of Health System Pharmacists, Society of Infectious Diseases Pharmacists, and The Joint Commission.

CDC recognizes that there is no "one size fits all" approach to optimize antibiotic use for all settings. The complexity of medical decision-making surrounding antibiotic use and the variability in facility size and types of care in U.S. healthcare settings require flexible programs and activities.

Core Elements of Hospital Antibiotic Stewardship Programs

Core Elements of Outpatient Antibiotic Stewardship

Core Elements of Antibiotic Stewardship for Nursing Homes

Implementation of Antibiotic Stewardship Core Elements at Small and Critical Access Hospitals

Antimicrobial Stewardship Core Elements



LEADERSHIP COMMITMENT

ACCOUNTABILITY & DRUG EXPERTISE

EDUCATE & ACTION

TRACKING AND REPORTING



The Core Elements of Outpatient Antibiotic Stewardship Clinician Checklist



Avoid Antibiotics for Inappropriate Indications

- ✓ Upper respiratory tract infections (URTIs)
 - Colds, acute bronchitis, non-streptococcal pharyngitis
- ✓ Early or mild sinusitis
 - > 90% of patients with acute sinusitis are given antibiotics, but essentially 80-90% of URIs are viral
- ✓ Asymptomatic bacteriuria (ASB)

Little or no potential benefits which are significantly outweighed by potential harms

Six ways to improve Antibiotic Appropriateness in Community Settings

- ✓ Employ “watch and wait” or “delayed prescribing”
- ✓ Limit antibiotic duration
- ✓ Improve fluoroquinolone prescribing practices
- ✓ Do not treat viral upper respiratory tract infections
- ✓ Avoid prolonged antibiotic use
- ✓ Avoid prophylactic antibiotic use


#1: Employ watch and wait

- Documentation of the indication for every antibiotic order can inform antibiotic selection and help determine the appropriate duration of treatment
- Alert the provider if the indication of an antibiotic order is not provided

“Core Elements of Antibiotic Stewardship for Nursing Homes.” Centers for Disease Control and Prevention, Centers for Disease Control and Prevention, 30 Oct, 2018, <https://www.cdc.gov/longtermcare/prevention/antibiotic-stewardship.html>
Appendix PP State Operations Manual. Centers for Medicare and Medicaid Services, Revised 11/22/2017, <https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/GuidanceforLawsAndRegulations/Downloads/Appendix-PP-State-Operations-Manual.pdf>

Adult Treatment Recommendations

Condition	Epidemiology	Diagnosis	Management
Acute rhinosinusitis ^{1,2}	<ul style="list-style-type: none"> About 1 out of 8 adults (12%) in 2012 reported receiving a diagnosis of rhinosinusitis in the previous 12 months, resulting in more than 30 million diagnoses Ninety-98% of rhinosinusitis cases are viral, and antibiotics are not guaranteed to help even if the causative agent is bacterial. 	<ul style="list-style-type: none"> Diagnose acute <u>bacterial</u> rhinosinusitis based on symptoms that are: <ul style="list-style-type: none"> Severe (>3-4 days), such as a fever $\geq 39^{\circ}\text{C}$ (102°F) and purulent nasal discharge or facial pain; Persistent (>10 days) without improvement, such as nasal discharge or daytime cough; or Worsening (3-4 days) such as worsening or new onset fever, daytime cough, or nasal discharge after initial improvement of a viral upper respiratory infections (URI) lasting 5-6 days. Sinus radiographs are not routinely recommended. 	<p>If a bacterial infection is established:</p> <ul style="list-style-type: none"> Watchful waiting is encouraged for uncomplicated cases for which reliable follow-up is available. Amoxicillin or amoxicillin/clavulanate is the recommended first-line therapy. Macrolides such as azithromycin are not recommended due to high levels of <i>Streptococcus pneumoniae</i> antibiotic resistance (~40%). For penicillin-allergic patients, doxycycline or a respiratory fluoroquinolone (levofloxacin or moxifloxacin) are recommended as alternative agents.



Adult Treatment Recommendations

Condition	Epidemiology	Diagnosis	Management
Pharyngitis ^{8,9}	<ul style="list-style-type: none"> Group A beta-hemolytic streptococcal (GAS) infection is the only common indication for antibiotic therapy for sore throat cases. Only 5–10% of adult sore throat cases are caused by GAS. 	<ul style="list-style-type: none"> Clinical features alone do not distinguish between GAS and viral pharyngitis; a rapid antigen detection test (RADT) is necessary to establish a GAS pharyngitis diagnosis Those who meet two or more Centor criteria (e.g., fever, tonsillar exudates, tender cervical lymphadenopathy, absence of cough) should receive a RADT. Throat cultures are not routinely recommended for adults. 	<ul style="list-style-type: none"> Antibiotic treatment is NOT recommended for patients with negative RADT results. Amoxicillin and penicillin V remain first-line therapy due to their reliable antibiotic activity against GAS. For penicillin-allergic patients, cephalexin, cefadroxil, clindamycin, or macrolides are recommended. GAS antibiotic resistance to azithromycin and clindamycin are increasingly common. Recommended treatment course for all oral beta lactams is 10 days.



Viruses or Bacteria

What's got you sick?

Antibiotics are only needed for treating certain infections caused by bacteria. Viral illnesses cannot be treated with antibiotics. When an antibiotic is not prescribed, ask your healthcare professional for tips on how to relieve symptoms and feel better.

Common Condition	Common Cause			Are Antibiotics Needed?
	Bacteria	Bacteria or Virus	Virus	
Strep throat	✓			Yes
Whooping cough	✓			Yes
Urinary tract infection	✓			Yes
Sinus infection		✓		Maybe
Middle ear infection		✓		Maybe
Bronchitis/chest cold (in otherwise healthy children and adults)*		✓		No*
Common cold/runny nose			✓	No
Sore throat (except strep)			✓	No
Flu			✓	No

* Studies show that in otherwise healthy children and adults, antibiotics for bronchitis won't help you feel better.

#2 Limit Antibiotic Duration

- Guidelines for treatment duration are available for common infectious diseases, such as pneumonia, urinary tract infection, and skin and soft tissue infection
- Contact the provider if the length of antibiotic treatment exceeds the recommended duration

Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis.* 2007;44 Suppl 2:S27-72.

Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis.* 2016


Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 Update by the Infectious Diseases Society of America. *Clin Infect Dis.* 2014;59(2):e10-52.

#3: Improve Fluoroquinolone Prescribing

- Due to risk of serious adverse events, the U.S. Food and Drug Administration issued a boxed warning to limit fluoroquinolone prescribing in specific conditions, such as acute bacterial sinusitis and uncomplicated urinary tract infections, where other treatment options are available
- When possible, discuss alternatives to fluoroquinolones with providers

“FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects.”
U.S. Food and Drug Administration, Centers for Disease Control and Prevention, Centers for Disease Control and Prevention, 26 Oct. 2017,
<https://www.fda.gov/Drugs/DrugSafety/ucm511530.htm>

The History of Fluoroquinolones



<https://www.fda.gov/Drugs/DrugSafety/ucm628753.htm>
<https://www.fda.gov/Drugs/DrugSafety/ucm511530.htm>

Risks outweigh the benefits for certain conditions including patients with uncomplicated UTI

#4: Avoid Treatment of Asymptomatic Bacteriuria

- Nursing Home residents with asymptomatic bacteriuria should not be treated with antibiotics in most cases
- Advocate for the use of protocols that help providers evaluate for urinary tract infection specific signs and symptoms before testing for urinary tract infection and the starting antibiotics

Nicolle LE, Bradley S, Colgan R, et al. Clin Infect Dis. 2005;40(5):643-54.

Loeb M, [Bentley DW](#), [Bradley S](#), et al.. Infect Control Hosp Epidemiol. 2001; 22(2): 120-124.

“Suspected UTI SBAR Form, June 2014, https://www.ahrq.gov/sites/default/files/wysiwyg/nhguide/4_TK1_T1-SBAR_UTI_Final.pdf

Loeb M, Brazil K, Lohfield L et al.. [BMJ](#). 2005 Sep 24;331(7518):669.

Adult Treatment Recommendations



Condition	Epidemiology	Diagnosis	Management
<p>Acute uncomplicated cystitis^{10,11}</p>	<ul style="list-style-type: none"> Cystitis is among the most common infections in women and is usually caused by <i>E. coli</i>. 	<ul style="list-style-type: none"> Classic symptoms include dysuria, frequent voiding of small volumes, and urinary urgency. Hematuria and suprapubic discomfort are less common. Nitrites and leukocyte esterase are the most accurate indicators of acute uncomplicated cystitis 	<p>For acute uncomplicated cystitis in healthy adult non-pregnant, premenopausal women:</p> <ul style="list-style-type: none"> Nitrofurantoin, trimethoprim/sulfamethoxazole (TMP-SMX, where local resistance is <20%), and fosfomycin are appropriate first-line agents. Fluoroquinolones (e.g. ciprofloxacin) should be reserved for situations in which other agents are not appropriate.

<https://www.cdc.gov/antibiotic-use/community/for-hcp/outpatient-hcp/index.html> Accessed: September 10, 2021

#5: Limit the Use of Prolonged Antibiotic Prophylaxis for Urinary Tract Infection

- There is no clear evidence supporting prolonged antibiotic use for the prevention of recurrent urinary tract infections in nursing home residents with asymptomatic bacteriuria
- Identify residents on prolonged antibiotic therapy for prevention of urinary tract infection and discuss the benefits and risks of prolonged antibiotic use with providers

Thompson ND, LaPlace L, Epstein L, et al.. [J Am Med Dir Assoc.](#) 2016 Dec 1;17(12):1151-1153.

Albert X, [Huertas J](#), [Pereiró JJ](#), et al. [Cochrane Database Syst Rev.](#) 2004;(3):CD001209.

Giannella M, Tedeschi S, Bartoletti M, et al. [Expert Rev Anti Infect Ther.](#) 2016;14(2):219-30.

Ahmed H, Davies F, Francis N, et al. [BMJ Open.](#) 2017 May 29;7(5):e015233.

Patients requesting Antibiotics?

What do I tell my patients if antibiotics are not deemed necessary?

Do antibiotics have side effects?



Any time antibiotics are used, they can cause side effects. However, antibiotics can save lives. When you need antibiotics, the benefits outweigh the risks of side effects. If you don't need antibiotics, you shouldn't take them because they can cause harm.

Common side effects of antibiotics include:



Rash



Dizziness



Nausea



Yeast Infection



Diarrhea

Get immediate medical help if you experience severe diarrhea. It could be a symptom of a **C. difficile infection** (also called **C. diff**), which can lead to severe colon damage and death. People can also have severe and life-threatening allergic reactions.

If you experience side effects, follow up with your healthcare professional.

To learn more about antibiotic prescribing and use, visit www.cdc.gov/antibiotic-use or call 1-800-CDC-INFO.

1 out of 5

medication-related visits to the emergency room are from reactions to antibiotics.



CS320411-A

KNOWLEDGE CHECKS

Question 1

Which of the following is incorrect about antibiotic misuse and how it has led to antimicrobial resistance and a subsequent public health emergency?

- A. Antibiotics are given when they are not needed (i.e. viral infections and asymptomatic bacteriuria)
- B. Antibiotics are continued when they are no longer necessary
- C. Antibiotics are given at the wrong dose (under-dosed)
- D. Antibiotics given at the correct dose, duration and only when needed improve outcomes

Question 2

True or False: Antimicrobial Stewardship is defined as: Coordinated interventions designed to improve and measure the appropriate use of antimicrobials by promoting the selection of the optimal antimicrobial drug regimen, dose, duration of therapy, and route of administration?

- A. True
- B. False

Question 3

Which of the following is accurate about how a syndromic stewardship approach focuses efforts in community settings ?

- A. Improved clinical outcomes through focusing interdisciplinary efforts
- B. Focusing on the pharmacist alone to improve outcomes
- C. Focusing on the prescriber alone to improve outcomes
- D. Focusing on the educating the patient to improve outcomes

Question 4

Which of the following is accurate about effective implementation practices for antimicrobial stewardship in community settings?

- A. Leadership commitment
- B. Tracking and reporting antibiotic use metrics
- C. Naming a champion for accountability
- D. Educating and taking action
- E. All of the above are correct

Question 5

Which of the following is accurate about improving appropriate antibiotic use (AU) in community settings?

- A. Employ “watch and wait” or “delayed prescribing”
- B. Improve fluoroquinolone prescribing practices
- C. Do not treat viral upper respiratory tract infections
- D. Avoid prophylactic antibiotic use
- E. All of the above are accurate

Antibiotic OVERUSE in Our Community;

A call to action

Kerry L. LaPlante, Pharm.D., FCCP, FIDSA

Chairperson, Antimicrobial Stewardship and Environmental Cleaning Task Force, Rhode Island Department of Health
Department Chairperson and Professor of Pharmacy, University of Rhode Island, College of Pharmacy

Adjunct Professor of Medicine,
The Warren Alpert Medical School of Brown University

Senior Director of the Rhode Island Infectious Diseases Research (RIID) Program

Co-Director of Antimicrobial Stewardship Program, and Infectious Diseases Pharmacotherapy Specialist, Providence Veterans Medical Center

ANTIMICROBIAL STEWARDSHIP

SYSTEM-LEVEL INTERVENTIONS

Clara Ni, PharmD, BCIDP
Clinical Pharmacist – Antimicrobial Stewardship
MedStar Georgetown University Hospital

OBJECTIVES

Identify challenges of system-level work


Share strategies on how to address challenges of system-level work

Interpret the standardized antimicrobial administration ratio (SAAR)

CDC Core Elements



GENERAL CHALLENGES OF SYSTEM-LEVEL WORK



Standard System

ATRIUM HEALTH

Location	Southeast
System	28 acute care facilities 67.9% ≤200 beds 35.7% without ID consult service access (tele or in-person) 4 different electronic medical record systems
System-Level Resources	Medical director 2 FTE clinical pharmacist 1 FTE data analyst

FTE: full time equivalent

ATRIUM HEALTH

System-Level Structure	<p>Bimonthly system wide meeting</p> <p>Monthly coaching call with central advisory team: review data trends, discuss targets, monthly DOT data, education</p> <p>Site visits</p>
Opportunities	<p>Education: annual symposium, newsletter, empiric antibiotic therapy guidelines</p> <p>Maximizing/creating resources:</p> <ul style="list-style-type: none"> • Integrate responsibilities into existing daily rounds • Hospitals without ID MD/RPh – relied on routine access to system level resources • Business plan for dedicated stewardship pharmacist <p>Optimizing technology: integrate CDS system into work flow</p> <p>Communication (amongst local level groups)</p> <ul style="list-style-type: none"> • local multidisciplinary ASC • incorporate into another standing committee

ASC: Antibiotic subcommittee; CDS: clinical decision support; DOT: days of therapy

ATRIUM HEALTH - Outcomes




Figure 1: Bar graph of cumulative antibiotic days of therapy (DOT) for 2016 by facility in relation to baseline (red line), target goal (green line), and stretch goal (blue line). Bar graphs are color coded by goal achievements (blue: stretch goal achieved; green: target goal achieved; orange: decreased DOT from baseline but target not attained; red: increased DOT from baseline). Hospitals are listed in order of monthly patient census (lowest to highest). LH, large hospital (> 200 beds); SH, small hospital (51–200 beds); CAH, critical access hospital (≤ 50 beds); *3-hospital regional network; **3-hospital regional network; ***10-hospital regional network.

BJC HEALTHCARE

Location	Midwest
System	13 acute care facilities 46.2% ≤200 beds
System-Level Resources	0.35 FTE ID physician 0.6 FTE clinical pharmacist 0.5 FTE RN • 60 members system-wide

Table 1. BJC HealthCare System Hospitals

Hospital	Type	No. Staffed Beds	Approximate Pharmacist FTE^a	Approximate Physician FTE^a
A	Urban academic adult tertiary care	1,342	1.0	0.5
B	Suburban community	497	0.2	0.01
C	Suburban community	485	0.8	0.01
D	Suburban community	397	0.2	0.05
E	Urban academic pediatric tertiary care	280	1.0	0.5
F	Suburban community	216	0.5	0.05
G	Suburban community	206	0.03	0.01
H	Rural critical access	133	0.05	0.01
I	Suburban community	127	0.25	0.01
J	Suburban community	113	0.2	0.05
K	Suburban community	72	0.25	0.01
L	Suburban community	67	0.5	0.05
M	Rural critical access	35	0.02	0.01

^aFTE = full-time equivalent.

BJC HEALTHCARE

System-Level Structure	Bimonthly system wide meeting
Opportunities	<p>Education: local/national/online training, regional conferences</p> <p>Maximizing/creating resources:</p> <ul style="list-style-type: none"> • Contract ASP MD • Hospitalist as ASP champion <p>Optimizing technology (CDS)</p> <p>Reporting</p> <ul style="list-style-type: none"> • Local benchmarking: Tableau dashboard by drug, drug class, NHSN drug categories, unit, DRG • National benchmarking: NHSN AU and AR modules <p>Leadership support</p>

DRG: diagnosis related group

AVERA HEALTH


Location	Midwest (rural)
System	33 acute care facilities
System-Level Resources	ID physician (medical director) ID pharmacist (pharmacy lead) AVP Hospital Pharmacy (administrative lead)

AVP: assistant vice president

AVERA HEALTH

System-Level Structure	Bimonthly system wide meeting
Opportunities	Education: local/national/online training, regional conferences Maximizing/creating resources: <ul style="list-style-type: none">• Telemed ID• M-F ASP web-conference Optimizing technology (CDS) Reporting (Tableau) Leadership support

Levofloxacin DOT/1,000 Patient Days



^aAMCK = Avera McKennan Hospital and University Health Center, ASL = Avera St. Luke's, ASM = Avera St. Mary's, ASHH = Avera Sacred Heart, AQOP = Avery Queen of Peace, NA = not available.

UNIFYING FACTORS

Developing overarching system structure

Maximizing/creating resources

Optimizing technology

Reporting

Education/Training

Knowledge Check

Which of the following are common challenges when implementing antimicrobial stewardship across the system?

- A. Limited resources
- B. Lack of data/reporting
- C. Lack of leadership support
- D. All of the above

Knowledge Check

Which of the following strategies address a CDC Core Element?

- A. Holding an annual symposium on antimicrobial stewardship that provides continuing education for the healthcare team
- B. Naming an Assistant Vice President of Hospital Pharmacy as a member of the system-level antimicrobial stewardship committee
- C. Using data visualization software to track and report antimicrobial usage
- D. All of the above


MEDSTAR HEALTH

Not-for-profit

Baltimore-Washington, D.C.

10 hospitals

- 9 acute care
- 1 rehabilitation facility



MEDSTAR HEALTH

Acute Care Hospital	Type	No. Staffed Beds
1	Suburban teaching	338
2	Urban teaching	394
3	Suburban community teaching	214
4	Urban teaching	131
5	Suburban community	104
6	Rural	93
7	Rural	178
8	Urban teaching	185
9	Urban teaching	769

UNIFYING FACTORS

Developing overarching system structure


Maximizing/creating resources

Optimizing technology


Reporting

Education/Training

CORPORATE PHARMACY STRUCTURE




SYSTEM ASP STRUCTURE



- System Director Drug Use Policy
- Monthly
- Formulary standardization, review and feedback of CPG and proposed initiatives

- System Director Clinical Pharmacy Services
- Bimonthly
- 2 ID physicians
- Physician review and approval

CORPORATE TO FACILITIES



UNIFYING FACTORS

Developing overarching system structure

Maximizing/creating resources

Optimizing technology

Reporting


Education/Training

MAXIMIZING/CREATING RESOURCES

Hybrid local- and system-level resource


- Added to larger urban teaching hospital with existing 1 FTE ID pharmacist
- Provide assistance to local stewardship efforts
- Assist with running IDPCPC, system ASC

Corporate



Facilities

MAXIMIZING/CREATING RESOURCES



UNIFYING FACTORS

Developing overarching system structure


Maximizing/creating resources

Optimizing technology


Reporting

Education/Training

OPTIMIZING TECHNOLOGY




OPTIMIZING TECHNOLOGY



OPTIMIZING TECHNOLOGY

Improvements made when held accountable with data



UNIFYING FACTORS

Developing overarching system structure

Maximizing/creating resources

Optimizing technology

Reporting

Education/Training

REPORTING

Internal

- Pharmacy PI analytics manager
 - Workload metrics
 - Vancomycin AUC metrics
- Vendor analytics resource
 - EHR: antibiotic utilization dashboard
 - Vancomycin AUC software

External

- GPO database
- NHSN AU reporting

Filters


Request Start DTS
1/1/2021 7/29/2021

Entity
(All)


Task DSC
(All)

- Task DSC
- amikacin - pharmacy to ma...
 - Amikacin Monitoring Task
 - Apixaban - Pharmacy to Ma...
 - Dabigatran - Pharmacy to ...
 - Gentamicin Monitoring Task
 - Rivaroxaban - Pharmacy to ...
 - tobramycin - pharmacy to ...
 - Tobramycin Monitoring Task
 - vancomycin - Pharmacy to ...
 - Vancomycin Monitoring Task
 - Warfarin - Pharmacy to Ma...
 - Warfarin Monitoring Task

Workload by Month




Completed Tasks by Shift




Workload by Day

Request Start Month: 7
Week of Month: Week 2



Late & Completed by Shift





Vancomycin Dosing: Patient Demographics

Data are from Patients Discharged Between 01/01/2019 - 06/30/2019

Facility
 ((All))


Days of Therapy
 >1 DOT

Days Between Last Dose & Max SCr
 -98 3

Initial SCr and Post Outcomes
 ((All))



Patient Gender Distribution

Sex	Min Age	Average Age	Median Age	Max Age	# Patients
Female	18	63	64	118	3,132
Male	18	60	62	99	3,554
Grand Total	18	62	63	118	6,686



Summary of Vancomycin Levels Taken

Property	Value
Number of Levels	15,247
Levels Per Patient	2.3
Number of Patients with 1 Level	1,992
Number of Patients with 2+ Levels	3,295



Patient BMI Distribution

Antimicrobial Days of Therapy (DOT)

Start Date

End Date

Patient Population

Facility

Nurse Unit

Ordering Provider

Drug

Therapeutic Category

Encounter Type

Medical Service

Facility

Adjust Minimum Enco...







Ordering Provider

SAAR Age Category

All Ages

Indication

Power Plan



Patient Details

Start Date
1/1/2021

End Date
7/31/2021

Patient Population
Patients with at least 1 Antimc...

Drug
(All)

Therapeutic Category1
(All)

FIN

FIN Selection	
00000000	
00000001	
00000002	
00000003	
00000004	
00000005	
00000006	
00000007	
00000008	
00000009	
00000010	
00000011	
00000012	
00000013	
00000014	
00000015	
00000016	
00000017	
00000018	
00000019	
00000020	
00000021	
00000022	
00000023	
00000024	
00000025	
00000026	
00000027	
00000028	
00000029	
00000030	
00000031	
00000032	
00000033	
00000034	
00000035	
00000036	
00000037	
00000038	
00000039	
00000040	
00000041	
00000042	
00000043	
00000044	
00000045	
00000046	
00000047	
00000048	
00000049	
00000050	
00000051	
00000052	
00000053	
00000054	
00000055	
00000056	
00000057	
00000058	
00000059	
00000060	
00000061	
00000062	
00000063	
00000064	
00000065	
00000066	
00000067	
00000068	
00000069	
00000070	
00000071	
00000072	
00000073	
00000074	
00000075	
00000076	
00000077	
00000078	
00000079	
00000080	
00000081	
00000082	
00000083	
00000084	
00000085	
00000086	
00000087	
00000088	
00000089	
00000090	
00000091	
00000092	
00000093	
00000094	
00000095	
00000096	
00000097	
00000098	
00000099	
00000100	

Drug DOT Last 30 Days	
Drug	
vancomycin	6,590
cefTRIAxone	6,534
piperacillin-tazobactam	6,239
cefepime	2,864
azithromycin	1,774
ceFAZolin	2,832
doxycycline	2,153
metronIDAZOLE	1,615
meropenem	1,510
sulfamethoxazole-trimethoprim	1,610
fluconazole	1,096
ciprofloxacin	924
ampicillin-sulbactam	712
micalungin	639
clindamycin	603
ampicillin	591

Encounter Details						
Facility	FIN	Enc Type	Discharge Dt/Tm		Length of Stay	DRG1
	00000000	Inpatient	20	10 AM	10.229166667	Null
	00000001	Inpatient	20	1 PM	2.140972222	Null
	00000002	Inpatient	20	1 PM	3.116666667	Null
	00000003	Inpatient	20	1 PM	3.930555556	Null
	00000004	Inpatient	02	1 AM	0.952777778	Null
	00000005	Inpatient	20	1 PM	3.384027778	Null
	00000006	Inpatient	02	1 PM	4.072222222	Null
	00000007	Inpatient	20	10 AM	8.213194444	Null
	00000008	Inpatient	02	PM	1.426368889	Null
	00000009	Inpatient	20	10 PM	6.247222222	Null
	00000010	Inpatient	20	10 AM	5.236805556	Null
	00000011	Inpatient	02	PM	1.100694444	Null
	00000012	Inpatient	02	PM	5.156944444	Null
	00000013	Inpatient	20	1 PM	1.166666667	Null
	00000014	Inpatient	20	1 PM	3.216666667	Null
	00000015	Inpatient	02	PM	5	Null
	00000016	Inpatient	02	PM	1.117361111	Null

Order Details						
Admin Beg Dt Tm1	Admin End Dt Tm1	FIN	Drug	Drug Route1	Therapeutic Category1	Ordering Provider1
3/17/2021 4:01:13 PM	3/17/2021 4:01:13 PM	00000000	vancomycin	IVPB	glycopeptide antibiotics	James, James, MD
3/17/2021 4:01:18 PM	3/17/2021 4:01:18 PM	00000001	gentamicin	IVPB	aminoglycosides	James, James, MD
3/17/2021 4:04:50 PM	3/17/2021 4:04:50 PM	00000002	ceFAZolin	IV_Abs Push	cephalosporins	James, James, MD
3/17/2021 4:05:19 PM	3/17/2021 4:05:19 PM	00000003	ceFAZolin	Null	cephalosporins	James, James, MD
3/17/2021 4:06:46 PM	3/17/2021 4:06:46 PM	00000004	ciprofloxacin	Null	quinolones	James, James, MD
3/17/2021 4:06:58 PM	3/17/2021 4:06:58 PM	00000005	tobramycin	IVPB	aminoglycosides, respiratory I.	James, James, MD
3/17/2021 4:06:59 PM	3/17/2021 4:06:59 PM	00000006	vancomycin	IVPB	glycopeptide antibiotics	James, James, MD
3/17/2021 4:07:15 PM	3/17/2021 4:07:15 PM	00000007	cefepime	IVPB	cephalosporins	James, James, MD
			vancomycin	IVPB	glycopeptide antibiotics	James, James, MD
3/17/2021 4:08:16 PM	3/17/2021 4:08:16 PM	00000008	cefTRIAxone	IM	cephalosporins	James, James, MD
3/17/2021 4:08:17 PM	3/17/2021 4:08:17 PM	00000009	piperacillin-tazobactam	IVPB	penicillins	James, James, MD
3/17/2021 4:09:40 PM	3/17/2021 4:09:40 PM	00000010	aztreonam	IVPB	miscellaneous antibiotics	James, James, MD
3/17/2021 4:09:51 PM	3/17/2021 4:09:51 PM	00000011	piperacillin-tazobactam	IVPB	penicillins	James, James, MD
3/17/2021 4:11:01 PM	3/17/2021 4:11:01 PM	00000012	piperacillin-tazobactam	IVPB	penicillins	James, James, MD
3/17/2021 4:11:45 PM	3/17/2021 4:11:45 PM	00000013	ampicillin	IVPB	penicillins	James, James, MD
3/17/2021 4:11:55 PM	3/17/2021 4:11:55 PM	00000014	aztreonam	IVPB	miscellaneous antibiotics	James, James, MD
3/17/2021 4:14:24 PM	3/17/2021 4:14:24 PM	00000015	piperacillin-tazobactam	IVPB	penicillins	James, James, MD


External Benchmarking

Addressing provider resistance

- “Unique” patient population
- “Our patients are more critically ill”


Comparison of variance

- GPO database
- DOT by: drug **and** base-DRG
- Top 20 AMCs vs. internal hospital



NHSN

National Healthcare Safety Network



NHSN - Objectives

Evaluate antimicrobial use trends over time at the facility and national levels

Risk-adjusted inter and intra-facility antimicrobial use benchmarking

NHSN - Metrics

Days of therapy (“antimicrobial days”) per 1000 days present

$$\frac{\text{Drug specific antimicrobial days per patient care location per month}}{\text{Days present per patient care location per month}} \times 1000$$

$$\frac{\text{Drug specific antimicrobial days for all inpatient units in a facility per month}}{\text{Days present per facility wide inpatient per month}} \times 1000$$

Antimicrobial days per 100 admissions

$$\frac{\text{Drug specific antimicrobial days for inpatient units in a facility per month}}{\text{Admissions per facility wide inpatient per month}} \times 100$$

NHSN – Facility Mapping

Facility location is “mapped” to one CDC Location

CDC-defined Locations

- Acuity level
- Service type

Table 5. Location types able to generate SAARs

CDC Location Type	CDC Location Code	NSHN Healthcare Service Location (HL7) Code
Adult Locations		
Medical Critical Care	IN:ACUTE:CC:M	1027-2
Surgical Critical Care	IN:ACUTE:CC:S	1030-6
Medical-Surgical Critical Care	IN:ACUTE:CC:MS	1029-8
Medical Ward	IN:ACUTE:WARD:M	1060-3
Surgical Ward	IN:ACUTE:WARD:S	1072-8
Medical-Surgical Ward	IN:ACUTE:WARD:MS	1061-1
ONC General Hematology-Oncology Ward	IN:ACUTE:WARD:ONC_HONC	1232-8
Adult Step Down Unit	IN:ACUTE:STEP	1099-1

NHSN – SAAR

Standardized Antimicrobial Administration Ratio

$$SAAR = \frac{\text{Observed antimicrobial use}}{\text{Predicted antimicrobial use}}$$

For specific:

- Category of antimicrobial agent
- Patient care locations

CDC predictive models

Nationally aggregated data from 2017/2018

Separate predictive models for each antimicrobial agent category

- All antibacterial agents
- Narrow spectrum beta-lactam agents
- Broad spectrum for hospital-onset infections
- Broad spectrum for community-acquired infections
- Anti-MRSA agents
- High-risk CDI agents
- Anti-fungals for invasive candidiasis

NHSN – SAAR

Standardized Antimicrobial Administration Ratio

$$SAAR = \frac{\text{Observed antimicrobial use}}{\text{Predicted antimicrobial use}}$$

$SAAR > 1$	$SAAR = 1$	$SAAR < 1$
<ul style="list-style-type: none">• Observed > Predicted• + statistical significance = over-use?	<ul style="list-style-type: none">• Observed = Predicted• Appropriate use?	<ul style="list-style-type: none">• Observed < Predicted• + statistical significance = under-use?

SAAR alone not definitive

Statistically significant \neq clinically significant

NHSN - SAAR

National SAAR distributions

- Inform benchmarking decisions
- Ex: Antifungals in step-down units – set goal at 0.8?


Table 3. Pooled mean SAAR values by adult location type & SAAR antimicrobial agent category*

Adult SAAR Location Type	Adult SAAR Antimicrobial Agent Categories						
	All Antibacterial	BSHO	BSCA	GramPos	NSBL	CDI	Antifungal
Medical ICUs	0.985	0.979	0.900	1.009	0.915	1.126	0.868
Medical-Surgical ICUs	0.971	1.007	0.873	0.915	0.959	0.958	0.890
Surgical ICUs	0.947	0.943	0.977	0.896	0.817	1.087	1.102
Medical Wards	0.983	0.983	0.942	0.941	1.024	0.992	0.905
Medical-Surgical Wards	0.999	1.088	0.910	0.943	1.078	0.979	0.948
Surgical Wards	0.985	1.044	0.988	0.963	0.873	1.046	1.022
Step Down Units	0.934	0.933	0.879	0.900	0.972	0.938	0.834
General Hematology-Oncology Wards	1.043	1.051	0.991	1.011	1.055	1.078	1.009

*Refer to technical tables for 2019 SAAR distributions for each SAAR antimicrobial agent category by location type. Abbreviations: BSHO - Broad spectrum antibacterial agents predominantly used for hospital-onset infections; BSCA - Broad spectrum antibacterial agents predominantly used for community-acquired infections; GramPos - Antibacterial agents predominantly used for resistant Gram-positive infections (e.g., MRSA); NSBL - Narrow spectrum beta-lactam agents; CDI - Antibacterial agents posing the highest risk for CDI; Antifungal - Antifungal agents predominantly used for invasive candidiasis.

NHSN - SAAR

Can use NHSN Statistics Calculator to determine statistical significance between 2 SAAR values



Note: Data for example only.

Cannot calculate statistical significance when comparing more than 2 SAAR values.

Knowledge Check

DeAnthony is evaluating the SAAR value for anti-MRSA agents used in the medical ICUs at his hospital, Top Health Medical Center. The local SAAR value is 0.73 (p-value 0.003, 95% confidence interval 0.433, 0.867), while the 2019 pooled mean SAAR is 1.009. Which of the following is the most accurate interpretation of this data?

- A. A SAAR value significantly lower than the national SAAR distribution may be concerning for under-use
- B. The use of significantly fewer anti-MRSA agents at Top Health is indicative of successful stewardship efforts
- C. A statistically significant SAAR value less than 1 indicates overuse of antibiotics
- D. The SAAR value is not statistically significant, and doesn't allow for meaningful interpretation of anti-MRSA agents at Top Health

UNIFYING FACTORS

Developing overarching system structure

Maximizing/creating resources


Optimizing technology

Reporting

Education/Training

EDUCATION/TRAINING


New Initiative



General

- Institution tuition support for conference attendance, certificates
- Internal CE
- Direct feedback to pharmacists

Summary



Summary

System Structure

- Bimonthly meetings
- Monthly coaching calls
- Site visits
- Pharmacy specific committee
- Corporate structure providing stewardship support

Maximizing Resources

- Physician
 - Contract ASP MD
 - Telemed ID
 - Hospitalist as ASP champion
- ASP incorporated into staff RPh workflow
- System-level resources support hospitals without dedicated ID resources
- Split system/local level position

Summary

Optimizing Technology

- CDS
- Web-conferencing technology
- Use data for performance improvement

Reporting

- Local benchmarking
 - Tableau dashboard
 - Vendor supported analytics
- National benchmarking
 - NHSN AU/AR
 - GPO database

Education

- Institution tuition support
- Local/regional/national conferences
- Online certificates
- Annual symposium
- Newsletter
- Internally developed CE

ANTIMICROBIAL STEWARDSHIP

SYSTEM-LEVEL INTERVENTIONS

Clara Ni, PharmD, BCIDP
Clinical Pharmacist – Antimicrobial Stewardship
MedStar Georgetown University Hospital

DC | HEALTH

GOVERNMENT OF THE DISTRICT OF COLUMBIA

899 North Capitol Street NE, 5th Fl, Washington, DC 20002



dchealth.dc.gov



[@_DCHealth](https://twitter.com/_DCHealth)



[dchealth](https://www.instagram.com/dchealth)



[DC Health](https://www.facebook.com/DCHealth)